title: [The empirical antibiotic therapy of patients with acute leukemias: the results of a multicenter study].
abstract: OBJECTIVE
  To evaluate efficacy of ampicilline/sulbactame and fluconasole in the regimen of empirical antibiotic therapy in patients with acute leukemia.
  
  
  METHODS
  The trial covered 14 hematological departments of Russia and 1 of Ukraine. Acute myeloid leukemia patients were included. 92 cases of fever in 56 patients with analysis of efficacy in 66 cases were considered. At the first stage of empirical antibiotic therapy, cefoperason (4 g/day) and gentamycin (240 mg/day) were administered. If no response was reached, ampicilline/sulbactam (7.5 g/day) was added. This was the second stage. If no response occurred for 5 days the three drugs were joined by fluconasol (400 mg followed by 200 mg).
  
  
  RESULTS
  Fever of unclear genesis was cured in 82% (28 of 34), clinical infection--in 80% (20 of 25), microbiologically confirmed infection--in 4 of 7 cases. A complete response to the empirical antibiotic therapy was registered in 52 of 66 cases (79%). 7(10.5%) patients died of infectious complications. 7(10.5%) received other antibiotics.
authors.forename: G A
authors.initials: GA
authors.lastname: Kliasova
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
authors.forename: E N
authors.initials: EN
authors.lastname: Parovichnikova
authors.forename: V G
authors.initials: VG
authors.lastname: Isaev
authors.forename: T V
authors.initials: TV
authors.lastname: Tolkacheva
authors.forename: V A
authors.initials: VA
authors.lastname: Rossiev
authors.forename: L B
authors.initials: LB
authors.lastname: Filatov
authors.forename: V A
authors.initials: VA
authors.lastname: Tumakov
authors.forename: E N
authors.initials: EN
authors.lastname: Iarikova
authors.forename: G B
authors.initials: GB
authors.lastname: Rekhtman
authors.forename: A S
authors.initials: AS
authors.lastname: Pristupa
authors.forename: N V
authors.initials: NV
authors.lastname: Medvedeva
authors.forename: L N
authors.initials: LN
authors.lastname: Sharov
authors.forename: N N
authors.initials: NN
authors.lastname: Klimko
authors.forename: O N
authors.initials: ON
authors.lastname: Porokhona
authors.forename: V A
authors.initials: VA
authors.lastname: Lapin
authors.forename: T S
authors.initials: TS
authors.lastname: Kaporskaia
authors.forename: G I
authors.initials: GI
authors.lastname: Kaletin
mesh_terms: D000208:Acute Disease; D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002438:Cefoperazone / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005335:Fever of Unknown Origin / Q000188:drug therapy* / Q000209:etiology; D015725:Fluconazole / Q000627:therapeutic use*; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D012426:Russia; D013407:Sulbactam / Q000627:therapeutic use; D013997:Time Factors; D014455:Ukraine
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005839:Gentamicins; C035444:sultamicillin; D000667:Ampicillin; D002438:Cefoperazone; D015725:Fluconazole; D013407:Sulbactam